VEGFA and metastatic colorectal cancer: Bevacizumab (AvastinTM), the first approved anti-angiogenic drug, binds vascular endothelial growth factor (VEGF) and was approved by Food and Drug Administration for the treatment of metastatic colorectal cancer in 2004 [3].